Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 12, 2021

View Archived Issues

Regenxbio initiates phase I/II study of RGX-121 gene therapy

Tessa Therapeutics enrolling participants in phase II CHARIOT study of CD30.CAR-T therapy

Celon successfully completes phase Ia study of CPL-116

BenevolentAI begins first-in-human trial of BEN-2293 for atopic dermatitis

New cancer anorexia therapeutic target identified

Wistar Institute patents new antibacterials against Pseudomonas

Sinocelltech discloses new anti-VEGF antibodies

Amicus reports topline phase III data on AT-GAA for late-onset Pompe disease

FDA clears IND for trial of LYS-GM101 in GM1 gangliosidosis

Bristol Myers Squibb synthesizes IRAK-4 inhibitors

Harbin Boyicheng Biotechnology discloses new HER2-targeting nanobodies

Last patient completes final visit for NORSE THREE safety study of ONS-5010

Capella BioScience discovers anti-PD-L1 antibodies

Researchers describe activity of BNT-162b2 against SARS-CoV-2 mutations

Specialization improves synthetic circuits

Preclinical findings support the use of HMI-202 for treating MLD

InflaRx presents data from phase IIb SHINE study of vilobelimab

Data on HMI-203 from animal studies support its further development for treating MPS II

European Commission approves Ogluo to treat severe hypoglycemia

New phase I/II trial investigates JSP-191 in sickle cell disease

FDA approves Evkeeza for homozygous familial hypercholesterolemia

Tukysa approved in E.U. for HER2-positive locally advanced or metastatic breast cancer

AC Immune reports interim data from phase Ib/II study of anti-pTau vaccine candidate ACI-35.030

Spanish AEMPS approves CAR-T ARI-0001 for ALL

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...